Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,332,969
  • Shares Outstanding, K 135,183
  • Annual Sales, $ 195,990 K
  • Annual Income, $ -72,240 K
  • 60-Month Beta 1.57
  • Price/Sales 26.60
  • Price/Cash Flow N/A
  • Price/Book 52.67
Trade HALO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.50
  • Number of Estimates 3
  • High Estimate 0.59
  • Low Estimate 0.44
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +308.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.21 +46.71%
on 11/02/20
41.26 -3.25%
on 11/18/20
+8.82 (+28.36%)
since 10/23/20
3-Month
25.17 +58.60%
on 09/24/20
41.26 -3.25%
on 11/18/20
+11.77 (+41.81%)
since 08/21/20
52-Week
12.71 +214.08%
on 03/18/20
41.26 -3.25%
on 11/18/20
+20.75 (+108.24%)
since 11/22/19

Most Recent Stories

More News
Halozyme Raises Full Year 2020 Guidance

, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and license agreement with Horizon...

HALO : 39.89 (+1.12%)
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE(R) Technology

Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Horizon exclusive access to Halozyme's ENHANZE(R)...

HZNP : 69.92 (-0.33%)
HALO : 39.89 (+1.12%)
Uptrend Call Working As Halozyme Therape Stock Rises 37.5% (HALO)

SmarTrend identified an Uptrend for Halozyme Therape (NASDAQ:HALO) on October 13th, 2020 at $28.70. In approximately 1 month, Halozyme Therape has returned 37.48% as of today's recent price of $39.45....

HALO : 39.89 (+1.12%)
Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy

Novartis (NVS) enters into a license agreement with Mesoblast for remestemcel-L for the treatment of acute respiratory distress syndrome and other indications.

INCY : 81.60 (-0.40%)
NVS : 87.00 (-0.59%)
HALO : 39.89 (+1.12%)
MESO : 15.60 (+13.21%)
Red Light Holland and Halo Labs Announce Intention to Enter Oregon Medicinal Psilocybin Market

Toronto, Ontario--(Newsfile Corp. - November 20, 2020) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (""), and Halo Labs Inc. ("") (NEO: HALO) (OTC: AGEEF) (Germany: A9KN) are pleased to...

TRIP.CN : 0.080 (+6.67%)
TRUFF : 0.0645 (+5.56%)
HALO : 39.89 (+1.12%)
AGEEF : 0.0500 (-5.66%)
Red Light Holland and Halo Labs Announce Intention to Enter Oregon Medicinal Psilocybin Market

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

HALO : 39.89 (+1.12%)
AGEEF : 0.0500 (-5.66%)
TRIP.CN : 0.080 (+6.67%)
TRUFF : 0.0645 (+5.56%)
Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate

Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.

JNJ : 143.16 (-2.19%)
GILD : 59.64 (-0.78%)
GSK : 36.53 (-1.35%)
HALO : 39.89 (+1.12%)
Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference

, /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. , president and chief executive officer, will participate in a fireside chat presentation for the Piper Sandler 32...

HALO : 39.89 (+1.12%)
/R E P E A T -- Halo Signs Deal to Acquire Winberry Farms/

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated September 16, 2020 to its short form base shelf prospectus dated September 2, 2020....

HALO : 39.89 (+1.12%)
AGEEF : 0.0500 (-5.66%)
Halo Signs Deal to Acquire Winberry Farms

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated September 16, 2020 to its short form base shelf prospectus dated September 2, 2020....

HALO : 39.89 (+1.12%)
AGEEF : 0.0500 (-5.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected...

See More

Key Turning Points

2nd Resistance Point 40.94
1st Resistance Point 40.20
Last Price 39.89
1st Support Level 38.16
2nd Support Level 36.86

See More

52-Week High 41.26
Last Price 39.89
Fibonacci 61.8% 30.35
Fibonacci 50% 26.98
Fibonacci 38.2% 23.62
52-Week Low 12.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar